ProCE Banner Activity

SQUIRE: Improved Survival With Necitumumab + Gemcitabine/Cisplatin vs Gemcitabine/Cisplatin as First-line Treatment in Patients With Squamous NSCLC

Slideset Download
The efficacy benefit of necitumumab was observed for all patient subgroups with advanced squamous NSCLC, except for patients 70 years of age or older, and was not predicted by EGFR expression levels.

Released: June 28, 2016

Expiration: June 27, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Genentech Roche Virology

Lilly

Novartis Pharmaceuticals Corporation